A Multi-Center, Investigator-Masked, Randomized, Crossover, Equivalence Study of the Safety and Efficacy of Once Daily Brimonidine Tartrate 0.35% Ophthalmic Suspension Compared with Brimonidine Tartrate 0.1% Ophthalmic Solution (Alphagan® P 0.1%) Dosed Three Times Daily in Subjects with Open Angle Glaucoma, Chronic Angle Closure Glaucoma with Patent Iridotomy/Iridectomy, or Ocular Hypertension.

Trial Profile

A Multi-Center, Investigator-Masked, Randomized, Crossover, Equivalence Study of the Safety and Efficacy of Once Daily Brimonidine Tartrate 0.35% Ophthalmic Suspension Compared with Brimonidine Tartrate 0.1% Ophthalmic Solution (Alphagan® P 0.1%) Dosed Three Times Daily in Subjects with Open Angle Glaucoma, Chronic Angle Closure Glaucoma with Patent Iridotomy/Iridectomy, or Ocular Hypertension.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Brimonidine (Primary)
  • Indications Glaucoma; Open-angle glaucoma
  • Focus Therapeutic Use
  • Sponsors Sun Pharma Advanced Research Company
  • Most Recent Events

    • 19 Jul 2017 Status changed from recruiting to completed.
    • 05 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top